Log In
BCIQ
Print this Print this
 

MEDI4276

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionHER2 bispecific antibody-drug conjugate targeting Epidermal growth factor receptor 2 (HER2; EGFR2; ErbB2; neu)
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate; Bispecific antibody
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat HER2-expressing advanced solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today